Skip to navigation menu Skip to content
Informational Alert

Learn about progress on health equity and anti-racism efforts in Seattle Children’s fourth quarterly report.

Informational Alert

Seattle Children’s notifies affected patients about a data security incident.

Informational Alert

Featured Research

Findings from Seattle Children's Scientists

Anti-clotting pill may usurp current treatments in kids

Oct. 31, 2022 – Dr. Michael Portman in the Center for Integrative Brain Research and Division of Cardiology, along with an international research team, tested the safety and effectiveness of an anti-clotting pill in children.

Sleuthing the Source of a New Neurodevelopmental Disorder

Dr. Brock Grill and his lab members in the Center for Integrative Brain Research collaborated with an international research team to identify the molecular genetic cause of a new neurodevelopmental disorder.

Engineering B Cells for Future Therapies

Oct. 6, 2022 – Nature Communications published findings by Seattle Children’s Research Institute’s Drs. Richard James and David Rawlings about long-lived engineered B cells to deliver protein therapies.

New T-Cell Therapy May Treat or Prevent Type 1 Diabetes

Oct. 5, 2022 – Science Translational Medicine published new insights by Seattle Children’s Research Institute’s Dr. David Rawlings and Benaroya Research Institute’s Dr. Jane Buckner into promising T-cell therapy to treat type 1 diabetes.

Pinpointing the Origin of Deadly Brain Tumors

Sept. 21, 2022 – In two papers published in Nature, Dr. Kathleen Millen and her team are the first to identify the cells that give rise to the most aggressive forms of medulloblastoma.

One Bite Closer to a Malaria Vaccine

Sept. 1, 2022 – Science Translational Medicine published new findings by Seattle Children’s Research Institute’s Drs. Stefan Kappe and Ashley Vaughan and University of Washington’s Dr. Sean Murphy showing a genetically engineered parasite vaccine provides protection from controlled human malaria infection.

Identifying genetic regulators of opioid tolerance

Nature Neuroscience published new insights by SCRI’s Dr. Brock Grill and UF Scripps Biomedical Research’s Dr. Kirill Martemyanov into a molecular genetic mechanism that affects tolerance at the behavioral level.

“Future-proofing” against new COVID-19 variants

Aug. 8, 2022 – In findings published in the Journal of Experimental Medicine, SCRI’s Dr. David Rawlings and UW’s Dr. Marion Pepper discovered changing the structure of COVID antibodies better prevented against infection and against more virus variants.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies